biotech · Bladder Cancer · Non Muscle Invasive Bladder Cancer · CGON
CG Oncology
CG Oncology is a biotech organization headquartered in Dallas, USA. It trades on NYSE under ticker CGON. Primary therapeutic focus areas include Bladder Cancer, Non Muscle Invasive Bladder Cancer, Transitional Cell Carci
Dallas, USA HQ
2010 Founded
187 Employees
Public company Type
CGON · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dallas, USA
- Founded
- 2010
- Employees
- 187
- Programs
- 8
- Drugs
- 1
- Patents
- 5
CG0070
Phase 1 · small molecule · Muscle-Invasive Bladder Carcinoma
CG0070 for Muscle-Invasive Bladder Carcinoma is a Phase 1 program (small_molecule) at CG Oncology with 1 ClinicalTrials.gov record(s).
Internal code MCC-20575
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CG Oncology
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Muscle-Invasive Bladder Carcinoma
- Status
- completed
- Trials
- 1